# Clinical Application Study of [123I]Metaiodobenzylguanidine and Somatostatin Receptor-Targeted Imaging in the Diagnosis and Staging of Neuroblastoma

> **NCT07064746** · — · RECRUITING · sponsor: **Nanjing First Hospital, Nanjing Medical University** · enrollment: 150 (estimated)

## Conditions studied

- Neuroblastoma (NB)

## Interventions

- **DIAGNOSTIC_TEST:** ¹²³I-MIBG SPECT/CT
- **DIAGNOSTIC_TEST:** SSTR PET

## Key facts

- **NCT ID:** NCT07064746
- **Lead sponsor:** Nanjing First Hospital, Nanjing Medical University
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** RECRUITING
- **Start date:** 2022-07-10
- **Primary completion:** 2027-07-10
- **Final completion:** 2027-07-10
- **Target enrollment:** 150 (ESTIMATED)
- **Last updated:** 2025-07-21

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07064746

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07064746, "Clinical Application Study of [123I]Metaiodobenzylguanidine and Somatostatin Receptor-Targeted Imaging in the Diagnosis and Staging of Neuroblastoma". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT07064746. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*